Published 5 days ago • Updated 4 days ago

Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies

In 2024, Akeso Biopharma, led by Founder Xia Yu, achieved key milestones in innovative drug development, particularly with its bispecific antibodies, cadonilimab and ivonescimab.
Akeso's advancements stem from its unique integrated R&D innovation system, including the ACE Platform and Tetrabody technology, enabling it to develop first-in-class and best-in-class drugs.
Cadonilimab received approval for new indications, including first-line gastric cancer addressing unmet needs in PD-L1 low/negative populations and recurrent/metastatic cervical cancer, while ivonescimab was launched for EGFR-TKI-resistant nsq-NSCLC after demonstrating superior mPFS compared to pembrolizumab in a Phase III study.
Xia Yu stated, "We are thrilled to have reached historic milestones in our innovative drug development in 2024," and "The approval of several globally competitive products and breakthroughs in advanced therapies have strengthened our global competitiveness in biopharmaceutical innovation."
Akeso's new drug sales revenue surpassed RMB 2 billion in 2024, a 25% year-on-year increase, driven by adjustments in drug pricing and optimization of commercial systems, while ongoing Phase III trials for cadonilimab and ivonescimab, along with their inclusion in China's NRDL, are expected to further expand their reach and impact, and Summit Therapeutics is advancing the HARMONi studies for ivonescimab with topline data expected in mid-2025, and plans for a clinical collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer's ADCs.

Insights by Ground AI

Does this summary seem wrong?

48 Articles

All

Left

Center

Right

Rutland Herald

+46 Reposted by 46 other sources

Center

Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies

Key Highlights:

5 days ago

Read Full Article

pressreach.com

Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies - PressReach

Key Highlights: Global first “immuno + anti-vascular” bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS HR=0.51; sNDA under priority review. Cadonilimab approved for first-line gastric cancer: Fills immunotherapy gap for patients with low or negative PD-L1 expressi…

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year